American Heart Association

Cutting Daily Sodium Intake Significantly Lowers Blood Pressure in 1 Week, According to New Research
November 15, 2023

AHA 2023: Reducing daily sodium intake by about 4000 mg significantly lowered SBP in approximately 73% of adults in 1 week when compared to a higher sodium diet.

Social Vulnerabilities Linked to Cardiometabolic Risk in Pregnant Women in US, New Study Finds
November 09, 2022

AHA 2022: Study authors say more research is needed to investigate the impact of targeting social determinants of health to improve cardiometabolic risk and mortality in pregnant women.

Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
November 09, 2022

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Study: “Worrisome” Changes in Cardiovascular Function Immediately after Vaping, Smoking Traditional Cigarettes
November 04, 2022

AHA 2022: Chronic users of either e-cigarettes or traditional cigarettes had acute changes in cardiovascular function and performed worse on exercise stress testing than never users in new study.

Wearable Device Uptake Low Among Adults with Cardiovascular Disease, Nationally Representative Study Finds
November 02, 2022

AHA 2022: An estimated 18% of Americans with heart disease reported using wearables, compared with 29% of the total US population.

Perceived Discrimination Impairs Post-MI Recovery in Young Adults, Study Warns
November 02, 2022

AHA 2022. A perception of discrimination was associated with worse mental health and disease-related health status 1 year post-MI among adults aged ≤55 years.

Oral PCSK9 Inhibitor Significantly Reduced High Levels of Cholesterol in Phase 1 Trials
November 18, 2021

AHA 2021: New research showed MK-0616, an investigative oral PCSK9 inhibitor, was associated with a near 65% decrease in LDL-C.

First Sign of CVD in Smokers May be a Fatal MI or Stroke, New Study Finds
November 17, 2021

Smoking was associated with earlier onset of cardiovascular disease, by 5.1 years for men and 3.8 years for women, the new study found.

Canagliflozin Improved HF Symptoms, QOL Regardless of Diabetes Status in Fully Remote Clinical Trial
November 16, 2021

AHA 2021. Heart failure patients, across ejection fraction and diabetes status, reported improved QOL as early as 3 months in CHIEF-HF trial.